Kinase Inhibitor

Janus Kinase Inhibitors

Janus Kinase Inhibitor

Polycythemia Vera

Primary Myelofibrosis

<section class="Section" data-sectioncode="34089-3"><a name="LINK_5fa43624-d552-46ab-9679-0f37ec0aad5c"></a><a name="section-9"></a><h1>11 DESCRIPTION</h1>Ruxolitinib phosphate is a Janus kinase inhibitor with the chemical name (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate and a molecular weight of 404.36 g/mol. Ruxolitinib phosphate has the following structural formula: <img alt="structural formula" src="opzelura-1.jpg"/> Ruxolitinib phosphate is a white to off-white to light yellow to light pink powder.   OPZELURA (ruxolitinib) cream is a white to off-white oil-in-water, solubilized emulsion cream for topical use. Each gram of OPZELURA contains 15 mg of ruxolitinib (equivalent to 19.8 mg of ruxolitinib phosphate) in a cream containing cetyl alcohol, dimethicone 350, edetate disodium, glyceryl stearate SE, light mineral oil, medium chain triglycerides, methylparaben, phenoxyethanol, polyethylene glycol 200, polysorbate 20, propylene glycol, propylparaben, stearyl alcohol, purified water, white petrolatum, and xanthan gum. </section>

OPZELURA

ruxolitinib

ruxolitinib 15 MG/ML Topical Cream

Opzelura

ruxolitinib 15 MG/ML Topical Cream [Opzelura]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Opzelura is for mild to moderate eczema and nonsegmental vitiligo. It is intended for short-term and non-continuous use in people aged 12 and above who are not immunocompromised and for whom topical prescription therapies are not effective or not recommended.

Opzelura is FDA approved for the following indications: atopic dermatitis, nonsegmental vitiligo.

Report Adverse Event

Prescribing Information

Medication Guide 

Submit MSL Request 

Pharmacy List 

Coverage Authorization Request 

Coverage Authorization Appeal 

Letter of Medical Necessity 

Letter of Appeal - Additional Tube of Opzelura

Prescription & PAP Enrollment Form 

Prescription & Commercial Access Enrollment Form - Bridge Program 

Enroll in Patient Savings Program: Atopic Dermatitis 

Activate Copay Savings Card (If already have one) 

Enroll in Patient Savings Program: Nonsegmental Vitiligo

About Opzelura: Atopic Dermatitis 

Side Effects: Atopic Dermatitis 

Doctor Discussion Guide: Atopic Dermatitis 

Patient Stories: Atopic Dermatitis 

Patient Resources: Atopic Dermatitis

Patient Brochure: Atopic Dermatitis

 Patient Brochure (Spanish): Atopic Dermatitis 

Treatment Tracker: Atopic Dermatitis

Instructions For Use: Atopic Dermatitis

Comprehensive Support Program 

Doctor Discussion Guide: Nonsegmental Vitiligo

About Opzelura: Nonsegmental Vitiligo

Side Effects: Nonsegmental Vitiligo

App Download: Nonsegmental Vitiligo

Treatment Journal: Nonsegmental Vitiligo

Treatment Tracker: Nonsegmental Vitiligo

Instructions For Use: Nonsegmental Vitiligo